{"classes":[{"categories":[{"measurements":[{"comment":"Data for upper limit of CI was not estimable due to low number of participants with events.","groupId":"OG000","lowerLimit":"28.9","upperLimit":"NA","value":"40.2"},{"comment":"Data for median and upper limit of CI was not estimable due to low number of participants with events.","groupId":"OG001","lowerLimit":"12.1","upperLimit":"NA","value":"18.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"description":"PFS was defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression per Lugano classification or death from any cause. PD is defined in OM 6. KM estimates were used for analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with r/r B-cell iNHL subtype of FL received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"OG000","title":"Axicabtagene Ciloleucel (Follicular Lymphoma)"},{"description":"Participants with r/r B-cell iNHL subtype of MZL received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"OG001","title":"Axicabtagene Ciloleucel (Marginal Zone Lymphoma)"}],"paramType":"MEDIAN","populationDescription":"Participants in the Full Analysis Set with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 85.6 months","title":"Progression-free Survival (PFS) Per Lugano Classification by Central Assessment","type":"SECONDARY","unitOfMeasure":"months"}